Skip to content
value.today

RayzeBio, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2020
Total raised
$396 M
4 rounds on record
Latest round
$168 M
Aug 2022
First round on record
Aug 2020
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of RayzeBio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2022$168 MNo. 4$50 to $250 million

RayzeBio, Inc.: Raise no. 4, Aug 2022

Investors in this round

18 investors had bought by the notice of Sep 22, 2022: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for RayzeBio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$168 M of $168 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Preferred Stock can convert to the underlying shares of Common Stock.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arvind Kush · Executive Officer
  • Aubrey Haddach · Executive Officer
  • Ken Song · Executive Officer, Director
  • Aaron Kantoff · Director
  • Aaron Royston · Director
  • Alex Rosen · Director
  • Angie You · Director
  • Jerel Davis · Director
  • Maha Katabi · Director
  • Mary Tagliaferri · Director
  • Yi Larson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $8,146,506.12 of shares of Common Stock issued pursuant to a license agreement.”

Signed by Ken Song, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 22, 2022. Read the notice at the SEC.

equitySEC
Jun 2021$109 MNo. 3$50 to $250 million

RayzeBio, Inc.: Raise no. 3, Jun 2021

Investors in this round

23 investors had bought by the notice of Jun 10, 2021: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for RayzeBio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$109 M of $109 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Preferred Stock can convert to the underlying shares of Common Stock.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Deborah Charych · Executive Officer
  • Ken Song · Executive Officer, Director
  • Aaron Kantoff · Director
  • Aaron Royston · Director
  • Bong Koh · Director
  • Jerel Davis · Director
  • Yi Larson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $530,532 of shares of Common Stock issued pursuant to a license agreement.”

Signed by Ken Song, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 10, 2021. Read the notice at the SEC.

equitySEC
Nov 2020$105 MNo. 2$50 to $250 million

RayzeBio, Inc.: Raise no. 2, Nov 2020

Investors in this round

17 investors had bought by the notice of Dec 1, 2020: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for RayzeBio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$105 M of $105 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Preferred Stock can convert to the underlying shares of Common Stock.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ken Song · Executive Officer, Director
  • Aaron Kantoff · Director
  • Aaron Royston · Director
  • Bong Koh · Director
  • Jerel Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ken Song, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 1, 2020. Read the notice at the SEC.

equitySEC
Aug 2020$15 MNo. 1$10 to $50 million

RayzeBio, Inc.: Raise no. 1, Aug 2020

Investors in this round

9 investors had bought by the notice of Nov 9, 2020: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for RayzeBio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $45 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Preferred Stock can convert to the underlying shares of Common Stock.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ken Song · Executive Officer, Director
  • Aaron Kantoff · Director
  • Aaron Royston · Director
  • Jerel Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ken Song, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 9, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • RayzeBio, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2022).

    SEC Form D · Sep 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2022

That is all the official record says: RayzeBio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

20 named in official filings. Open an investor to see everything it has backed.

Investors in RayzeBio, Inc.
InvestorKindAmountRoundRoleSource
Redmile Biopharma Investments II, L.P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
venBio Global Strategic Fund III, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Venbio Global Strategic GP III, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Venbio Global Strategic GP III, LTDCompanynot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Versant Vantage I GP-GP, LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Versant Vantage I GP, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Versant Vantage I, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Versant Venture Capital VII, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Versant Ventures VII GP-GP, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Versant Ventures VII GP, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Viking Global Investors LPFund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Viking Global Opportunities Drawdown (Aggregator) LPFund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Viking Global Opportunities Drawdown GP LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Viking Global Opportunities Drawdown Portfolio GP LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Viking Global Opportunities GP LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Viking Global Opportunities Illiquid Investments Sub-Master LPFund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Viking Global Opportunities Parent GP LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Viking Global Opportunities Portfolio GP LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2023)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by RayzeBio, Inc.
NameRoleNamed in
Arvind KushExecutive officerSep 2022
Aubrey HaddachExecutive officerSep 2022
Ken SongExecutive officerSep 2022
Deborah CharychExecutive officerJun 2021
Aaron KantoffDirectorSep 2022
Aaron RoystonDirectorSep 2022
Alex RosenDirectorSep 2022
Angie YouDirectorSep 2022
Jerel DavisDirectorSep 2022
Ken SongDirectorSep 2022
Maha KatabiDirectorSep 2022
Mary TagliaferriDirectorSep 2022
Yi LarsonDirectorSep 2022
Bong KohDirectorJun 2021